GNTA (Genenta Science SPA) ROCE %: -26.07% (As of Dec. 2025)


GNTA Genenta Science SPA GNTA
31 GF Score
Price $1.53
! 4 Warning Signs
View Full Analysis

What is Genenta Science SPA ROCE %?

Genenta Science SPA GNTA -5.26% 31 ROCE % is -26.07% as of Dec. 2025. GuruFocus rates GNTA with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genenta Science SPA's annualized ROCE % for the quarter that ended in Dec. 2025 was -26.07%.

Genenta Science SPA  (NAS:GNTA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genenta Science SPA ROCE % Related Terms

Genenta Science SPA ROCE % Historical Data

* Premium members only.

The historical data trend for Genenta Science SPA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genenta Science SPA ROCE % Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -20.05 -30.37 -46.04 -57.11 -32.10

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.46 -47.68 -69.43 -42.94 -26.07
GNTA
31GF Score
Genenta Science SPA GNTA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genenta Science SPA ROCE % Calculation

Genenta Science SPA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7.733/( ( (15.523 - 2.198) + (37.341 - 2.48) )/ 2 )
=-7.733/( (13.325+34.861)/ 2 )
=-7.733/24.093
=-32.10 %

Genenta Science SPA's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-7.544/( ( (24.86 - 1.835) + (37.341 - 2.48) )/ 2 )
=-7.544/( ( 23.025 + 34.861 )/ 2 )
=-7.544/28.943
=-26.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -26.07% mean?
Genenta Science SPA (GNTA) has a ROCE % of -26.07% as of Dec. 2025.
Is Genenta Science SPA's ROCE % too high?
Genenta Science SPA's current ROCE % is -26.07%. Overall, Genenta Science SPA has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Genenta Science SPA's ROCE % compare to VRTX and REGN?
Genenta Science SPA's ROCE % of -26.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Genenta Science SPA's current ROCE % is -26.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genenta Science SPA stock overvalued right now?
Genenta Science SPA (GNTA) has a current ROCE % of -26.07%. The current ROCE % is -26.07%. Genenta Science SPA's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genenta Science SPA (GNTA), the current ROCE % is -26.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genenta Science SPA Business Description

Other Exchanges K5F:Germany
Address Via dell’Annunciata No. 31, Milan, ITA, 20121
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
31GF Score

Get the complete analysis for GNTA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price